Lotus Pharmaceutical, based in Tashkent, Uzbekistan, and founded in 1966, offers Cialis (tadalafil) as a branded product within its pharmaceutical portfolio. This medication is indicated for the treatment of erectile dysfunction and benign prostatic hyperplasia, addressing two common urological conditions in a single active pharmaceutical ingredient. The product was acquired from Eli Lilly for the Taiwan market.
As a tadalafil formulation, it belongs to a class of phosphodiesterase type 5 inhibitors widely used in therapeutic regimens for adult male patients. Sourcing buyers evaluating pharmaceutical catalog entries may consider this product for supply chains serving markets where these indications are prevalent. Lotus Pharmaceutical’s long-standing history since 1966 in Tashkent provides a baseline for assessing manufacturing tenure in the region.